STOCK TITAN

Lunai Bioworks cuts CEO base salary to $275K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Lunai Bioworks, Inc. (LNAI) amended and restated its employment agreement with David Weinstein, its chief executive officer and a director, effective October 14, 2026. His annual base salary is $275,000, reduced from $400,000 under the prior agreement, and he is not entitled to a bonus or equity award unless separately approved by the board. His at-will employment ends December 28, 2026, unless extended in writing.

The agreement defers $28,150.68 of October 2026 salary, payable without interest in a lump sum by the earlier of the end of employment and December 28, 2026, and in all events no later than March 15, 2027. Weinstein waived prior severance of six months’ base salary (approximately $200,000), continued benefits and accelerated vesting for termination without Cause or for Good Reason. Separately, LNAI’s Nasdaq delisting is expected on or about November 12, 2026; withdrawal of its Section 12(b) registration becomes effective 90 days after the November 2, 2026 Form 25 filing.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Nasdaq delisting is expected on or about November 12, 2026.

Filing Explained

The amendment ends Weinstein’s non-compete and non-solicitation duties, while confidentiality and invention-assignment obligations continue.

The company entered into the amended agreement on November 6, 2026, effective October 14, 2026, preserving compensation earned before that date and equity awards vested by then.

It also preserves Weinstein’s indemnification, expense-advancement, and directors’ and officers’ insurance rights.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Annual base salary under amended agreement $275,000 per year Beginning October 14, 2026
Annual base salary under prior agreement $400,000 per year Prior Agreement
Deferred October salary $28,150.68 October 2026 base salary; payable without interest by March 15, 2027, at the latest
Waived severance Approximately $200,000 Six months’ base salary under the prior agreement
Employment end date December 28, 2026 Unless extended by written agreement
Expected delisting date On or about November 12, 2026 Voluntary withdrawal from The Nasdaq Stock Market LLC
Section 12(b) withdrawal effective period 90 days After the Form 25 filing on November 2, 2026
at will technical
"Mr. Weinstein’s employment is at will"
Good Reason technical
"termination without Cause or for Good Reason"
accelerated vesting financial
"continued benefits and accelerated vesting"
A contract feature that makes stock awards, options, or restricted shares become owned or exercisable earlier than the original schedule. It shortens or cancels the waiting period so recipients can sell, transfer, or exercise their equity sooner — think of a timed lock that is unlocked ahead of schedule. It matters to investors because it changes when shares enter the market, who controls them, and how much dilution or ownership concentration happens.
Form 25 regulatory
"filed a Form 25 to voluntarily withdraw its common stock"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) regulatory
"withdrawal of registration under Section 12(b)"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
invention-assignment obligations technical
"confidentiality and invention-assignment obligations continue"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is David Weinstein’s salary under the LNAI agreement?

Under the amended agreement, David Weinstein’s annual base salary is $275,000 beginning October 14, 2026, down from $400,000; bonuses and equity awards require separate board approval.

When is LNAI expected to delist from Nasdaq?

LNAI’s delisting from The Nasdaq Stock Market LLC is expected to become effective on or about November 12, 2026. The company filed Form 25 on November 2, 2026; withdrawal of Section 12(b) registration becomes effective 90 days after that filing.

When will LNAI pay David Weinstein’s deferred October salary?

The $28,150.68 October 2026 base salary is deferred and payable in a lump sum without interest by the earlier of the end of employment and December 28, 2026, and in all events no later than March 15, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001527728 0001527728 2026-11-06 2026-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 6, 2026

 

LUNAI BIOWORKS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-38758 45-2259340
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

3400 Cottage Way, Suite G2, #32562

Sacramento, California 95825

(Address of principal executive offices) (Zip Code)

 

(424) 222-9301

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share LNAI The Nasdaq Stock Market LLC *

 

* On November 2, 2026, the Company filed a Form 25 to voluntarily withdraw its common stock from listing on The Nasdaq Stock Market LLC and from registration under Section 12(b) of the Securities Exchange Act of 1934. The delisting is expected to become effective on or about November 12, 2026; withdrawal of registration under Section 12(b) becomes effective 90 days after the Form 25 filing.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(e) On November 6, 2026, Lunai Bioworks, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement, dated as of November 2, 2026 and effective as of October 14, 2026 (the “Amended Agreement”), with David Weinstein, the Company’s Chief Executive Officer and a director. The Amended Agreement amends and restates Mr. Weinstein’s employment agreement dated as of October 14, 2024 (the “Prior Agreement”).

 

Under the Amended Agreement, Mr. Weinstein’s employment is at will and, unless extended by written agreement, ends on December 28, 2026. Beginning October 14, 2026, his annual base salary is $275,000, reduced from $400,000 under the Prior Agreement, and he is not entitled to any bonus or equity award unless separately approved by the Board of Directors. Payment of his October 2026 base salary of $28,150.68 is deferred and will be paid in a lump sum, without interest, on the earlier of the end of his employment and December 28, 2026, and in all events no later than March 15, 2027.

 

Mr. Weinstein waived his rights under the Prior Agreement to severance of six months’ base salary (approximately $200,000), continued benefits and accelerated vesting on a termination without Cause or for Good Reason, and waived any claim that the changes made by the Amended Agreement constitute Good Reason or a breach of the Prior Agreement. On termination for any reason he is entitled only to earned but unpaid base salary and unreimbursed business expenses. Compensation earned and unpaid under the Prior Agreement for periods before October 14, 2026, equity awards vested as of that date, and his indemnification, expense-advancement and directors’ and officers’ insurance rights are preserved. The non-competition and non-solicitation covenants in the Prior Agreement are terminated; confidentiality and invention-assignment obligations continue.

 

The foregoing description of the Amended Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description
10.1† Amended and Restated Employment Agreement, dated as of November 2, 2026, by and between Lunai Bioworks, Inc. and David Weinstein.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

† Management contract or compensatory plan or arrangement.

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LUNAI BIOWORKS, INC.
   
Date: November 12, 2026 By: /s/ David Weinstein
  Name: David Weinstein
  Title: Chief Executive Officer

 

3

 

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading